REFERENCES
1. Tucker BJ, Breaker RR. Riboswitches as versatile gene control elements. Curr Opin Struct Biol 2005;15:342-8.
3. Diener TO. Potato spindle tuber “virus”. IV. A replicating, low molecular weight RNA. Virology 1971;45:411-28.
4. Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A 1976;73:3852-6.
5. Zhan ZH, You ZH, Li LP, Zhou Y, Yi HC. Accurate prediction of ncRNA-protein interactions from the integration of sequence and evolutionary information. Front Genet 2018;9:458.
7. Fang XY, Pan HF, Leng RX, Ye DQ. Long noncoding RNAs: novel insights into gastric cancer. Cancer Lett 2015;356:357-66.
8. Weng W, Li H, Goel A. Piwi-interacting RNAs (piRNAs) and cancer: Emerging biological concepts and potential clinical implications. Biochim Biophys Acta Rev Cancer 2019;1871:160-9.
9. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426-37.
10. Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 2009;6:267-83.
11. Schwarzenbach H, Gahan PB. MicroRNA shuttle from cell-to-cell by exosomes and its impact in cancer. Noncoding RNA 2019;5.
12. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ. MicroRNAs as Novel Biomarkers for Breast Cancer. J Oncol 2009;2009:950201.
13. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014; doi: 10.1016/S0140-6736(13)62146-7.
14. McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 2016;7:418-9.
15. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 2019; doi: 10.3322/caac.21559.
16. Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol 2014;133:401-4.
17. Meinhold-Heerlein I, Hauptmann S. The heterogeneity of ovarian cancer. Arch Gynecol Obstet 2014;289:237-9.
18. Wong TS, Gao W, Chan JY. Transcription regulation of E-cadherin by zinc finger E-box binding homeobox proteins in solid tumors. Biomed Res Int 2014;2014:921564.
19. Tang HF, Massi D, Hemmings BA, Mandala M, Hu ZQ, et al. AKT-ions with a TWIST between EMT and MET. Oncotarget 2016;7:62767-77.
20. Satelli A, Li SL. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 2011;68:3033-46.
21. Ashaie MA, Chowdhury EH. Cadherins: the superfamily critically involved in breast cancer. Curr Pharm Des 2016;22:616-38.
22. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014;15:178-96.
23. Roane BM, Arend RC, Birrer MJ. Review: targeting the transforming growth factor-beta pathway in ovarian cancer. Cancers (Basel) 2019;11.
24. Arend RC, Londono-Joshi AI, Straughn JM Jr, Buchsbaum DJ. The Wnt/beta-catenin pathway in ovarian cancer: a review. Gynecol Oncol 2013;131:772-9.
25. Brzozowa-Zasada M, Piecuch A, Michalski M, Segiet O, Kurek J, et al. Notch and its oncogenic activity in human malignancies. Eur Surg 2017;49:199-209.
26. Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol 2019; doi: 10.1016/j.semcancer.2019.05.012.
27. Bilyk O, Coatham M, Jewer M, Postovit LM. Epithelial-to-mesenchymal transition in the female reproductive tract: from normal functioning to disease pathology. Front Oncol 2017;7:145.
28. Klymenko Y, Kim O, Stack MS. Complex determinants of epithelial: mesenchymal phenotypic plasticity in ovarian cancer. Cancers (Basel) 2017;9.
29. Barbolina MV. Molecular mechanisms regulating organ-specific metastases in epithelial ovarian carcinoma. Cancers (Basel) 2018;10.
30. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007;63:12-31.
31. Yang CH, Horwitz SB. Taxol((R)): the first microtubule stabilizing agent. Int J Mol Sci 2017;18.
32. Motohara T, Katabuchi H. Ovarian Cancer Stemness: Biological and Clinical Implications for Metastasis and Chemotherapy Resistance. Cancers (Basel) 2019;11.
33. Ottevanger PB. Ovarian cancer stem cells more questions than answers. Semin Cancer Biol 2017;44:67-71.
34. Liao JQ, Qian F, Tchabo N, Mhawech-Fauceglia P, Beck A, et al. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS One 2014;9.
35. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
36. Bondza PK, Maheux R, Akoum A. Insights into endometriosis-associated endometrial dysfunctions: a review. Front Biosci (Elite Ed) 2009;1:415-28.
37. Biggs WS, Marks ST. Diagnosis and Management of Adnexal Masses. Am Fam Physician 2016;93:676-81.
38. Yang WL, Lu Z, Bast RC Jr. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn 2017;17:577-91.
39. Abu Hassaan SO. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125. Dan Med J 2018;65.
40. Brenk A, Bodzek P, Balis M, Barbachowska A, Janosz I, et al. Usefulness of HE4 protein in differentiation of pelvic masses in woman. Prz Menopauzalny 2019;18:27-32.
41. Dewan R, Dewan A, Jindal M, Bhardawaj M. Diagnostic performance of serum human epididymis protein 4 (HE4) for prediction of malignancy in ovarian masses. Asian Pac J Cancer Prev 2019;20:1103-8.
43. Fabian MR, Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 2012;19:586-93.
45. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006;34:D140-4.
47. Ren H, Wang G, Chen L, Jiang J, Liu L, et al. Genome-wide analysis of long non-coding RNAs at early stage of skin pigmentation in goats (Capra hircus). BMC Genomics 2016;17:67.
48. Matsumoto A, Clohessy JG, Pandolfi PP. SPAR, a lncRNA encoded mTORC1 inhibitor. Cell Cycle 2017;16:815-6.
49. Anderson DM, Anderson KM, Chang CL, Makarewich CA, Nelson BR, et al. A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. Cell 2015;160:595-606.
50. Pauli A, Norris ML, Valen E, Chew GL, Gagnon JA, et al. Toddler: an embryonic signal that promotes cell movement via Apelin receptors. Science 2014;343:1248636.
51. Smith JE, Alvarez-Dominguez JR, Kline N, Huynh NJ, Geisler S, et al. Translation of small open reading frames within unannotated RNA transcripts in Saccharomyces cerevisiae. Cell Rep 2014;7:1858-66.
52. Ji Z, Song R, Regev A, Struhl K. Many lncRNAs, 5’UTRs, and pseudogenes are translated and some are likely to express functional proteins. Elife 2015;4:e08890.
53. Ma XY, Wang JH, Wang JL, Ma CX, Wang XC, et al. Malat1 as an evolutionarily conserved lncRNA, plays a positive role in regulating proliferation and maintaining undifferentiated status of early-stage hematopoietic cells. BMC Genomics 2015;16:676.
54. Kwok ZH, Tay Y. Long noncoding RNAs: lincs between human health and disease. Biochem Soc Trans 2017;45:805-12.
55. Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell 2018;172:393-407.
57. Sai Lakshmi S, Agrawal S. piRNABank: a web resource on classified and clustered Piwi-interacting RNAs. Nucleic Acids Res 2008;36:D173-7.
58. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2014;42:D68-73.
60. Griffiths-Jones S, Moxon S, Marshall M, Khanna A, Eddy SR, et al. Rfam: annotating non-coding RNAs in complete genomes. Nucleic Acids Res 2005;33:D121-4.
61. Girard A, Sachidanandam R, Hannon GJ, Carmell MA. A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature 2006;442:199-202.
62. Chen C, Liu J, Xu G. Overexpression of PIWI proteins in human stage III epithelial ovarian cancer with lymph node metastasis. Cancer Biomark 2013;13:315-21.
63. Aravin A, Gaidatzis D, Pfeffer S, Lagos-Quintana M, Landgraf P, et al. A novel class of small RNAs bind to MILI protein in mouse testes. Nature 2006;442:203-7.
64. Yin H, Lin H. An epigenetic activation role of Piwi and a Piwi-associated piRNA in Drosophila melanogaster. Nature 2007;450:304-8.
65. Huang XA, Yin H, Sweeney S, Raha D, Snyder M, et al. A major epigenetic programming mechanism guided by piRNAs. Dev Cell 2013;24:502-16.
66. Andersen PR, Tirian L, Vunjak M, Brennecke J. A heterochromatin-dependent transcription machinery drives piRNA expression. Nature 2017;549:54-9.
67. Aravin AA, Hannon GJ, Brennecke J. The Piwi-piRNA pathway provides an adaptive defense in the transposon arms race. Science 2007;318:761-4.
68. Wilson RC, Doudna JA. Molecular mechanisms of RNA interference. Annu Rev Biophys 2013;42:217-39.
69. Fu A, Jacobs DI, Zhu Y. Epigenome-wide analysis of piRNAs in gene-specific DNA methylation. RNA Biol 2014;11:1301-12.
70. Yan H, Wu QL, Sun CY, Ai LS, Deng J, et al. piRNA-823 contributes to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma. Leukemia 2015;29:196-206.
71. Watanabe T, Takeda A, Tsukiyama T, Mise K, Okuno T, et al. Identification and characterization of two novel classes of small RNAs in the mouse germline: retrotransposon-derived siRNAs in oocytes and germline small RNAs in testes. Genes Dev 2006;20:1732-43.
72. Li D, Luo Y, Gao Y, Yang Y, Wang Y, et al. piR-651 promotes tumor formation in non-small cell lung carcinoma through the upregulation of cyclin D1 and CDK4. Int J Mol Med 2016;38:927-36.
73. Yao J, Wang YW, Fang BB, Zhang SJ, Cheng BL. piR-651 and its function in 95-D lung cancer cells. Biomed Rep 2016;4:546-50.
74. Law PT, Qin H, Ching AK, Lai KP, Co NN, et al. Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma. J Hepatol 2013;58:1165-73.
75. Wang QE, Han C, Milum K, Wani AA. Stem cell protein Piwil2 modulates chromatin modifications upon cisplatin treatment. Mutat Res 2011;708:59-68.
76. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 2011;146:353-8.
77. Tay Y, Kats L, Salmena L, Weiss D, Tan SM, et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 2011;147:344-57.
78. Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011;147:358-69.
79. Muller V, Oliveira-Ferrer L, Steinbach B, Pantel K, Schwarzenbach H. Interplay of lncRNA H19/miR-675 and lncRNA NEAT1/miR-204 in breast cancer. Mol Oncol 2019;13:1137-49.
80. Zhang G, Sun H, Zhang Y, Zhao H, Fan W, et al. Characterization of dysregulated lncRNA-mRNA network based on ceRNA hypothesis to reveal the occurrence and recurrence of myocardial infarction. Cell Death Discov 2018;4:35.
81. Xia T, Liao Q, Jiang X, Shao Y, Xiao B, et al. Long noncoding RNA associated-competing endogenous RNAs in gastric cancer. Sci Rep 2014;4:6088.
82. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, et al. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010;465:1033-8.
83. An Y, Furber KL, Ji S. Pseudogenes regulate parental gene expression via ceRNA network. J Cell Mol Med 2017;21:185-92.
84. Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet 2012;13:271-82.
85. Lenkala D, LaCroix B, Gamazon ER, Geeleher P, Im HK, et al. The impact of microRNA expression on cellular proliferation. Hum Genet 2014;133:931-8.
87. Qi X, Zhang DH, Wu N, Xiao JH, Wang X, et al. ceRNA in cancer: possible functions and clinical implications. J Med Genet 2015;52:710-8.
88. de Giorgio A, Krell J, Harding V, Stebbing J, Castellano L. Emerging roles of competing endogenous RNAs in cancer: insights from the regulation of PTEN. Mol Cell Biol 2013;33:3976-82.
89. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
90. Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov 2013;3:1113-21.
91. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature 2014;505:344-52.
92. Do D, Bozdag S. Cancerin: a computational pipeline to infer cancer-associated ceRNA interaction networks. PLoS Comput Biol 2018;14:e1006318.
93. Arnberg AC, Van Ommen GJ, Grivell LA, Van Bruggen EF, Borst P. Some yeast mitochondrial RNAs are circular. Cell 1980;19:313-9.
94. Hsu MT, Coca-Prados M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature 1979;280:339-40.
96. Wang Y, Mo Y, Gong Z, Yang X, Yang M, et al. Circular RNAs in human cancer. Mol Cancer 2017;16:25.
98. Tatomer DC, Wilusz JE. An unchartered journey for ribosomes: circumnavigating circular RNAs to produce proteins. Mol Cell 2017;66:1-2.
99. Schneider T, Bindereif A. Circular RNAs: coding or noncoding? Cell Res 2017;27:724-5.
100. Liu KS, Pan F, Mao XD, Liu C, Chen YJ. Biological functions of circular RNAs and their roles in occurrence of reproduction and gynecological diseases. Am J Transl Res 2019;11:1-15.
101. Li Z, Huang C, Bao C, Chen L, Lin M, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol 2015;22:256-64.
102. Conn VM, Hugouvieux V, Nayak A, Conos SA, Capovilla G, et al. A circRNA from SEPALLATA3 regulates splicing of its cognate mRNA through R-loop formation. Nat Plants 2017;3:17053.
104. Ahmed I, Karedath T, Andrews SS, Al-Azwani IK, Mohamoud YA, et al. Altered expression pattern of circular RNAs in primary and metastatic sites of epithelial ovarian carcinoma. Oncotarget 2016;7:36366-81.
105. Xu Z, Yan Y, Zeng S, Dai S, Chen X, et al. Circular RNAs: clinical relevance in cancer. Oncotarget 2018;9:1444-60.
106. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11.
107. Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 1999;286:950-2.
108. Dana H, Chalbatani GM, Mahmoodzadeh H, Karimloo R, Rezaiean O, et al. Molecular mechanisms and biological functions of siRNA. Int J Biomed Sci 2017;13:48-57.
109. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005;12:461-6.
110. Landen CN, Kinch MS, Sood AK. EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets 2005;9:1179-87.
111. Singh A, Trivedi P, Jain NK. Advances in siRNA delivery in cancer therapy. Artif Cells Nanomed Biotechnol 2018;46:274-83.
112. Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release 2007;121:64-73.
113. Jere D, Jiang HL, Arote R, Kim YK, Choi YJ, et al. Degradable polyethylenimines as DNA and small interfering RNA carriers. Expert Opin Drug Deliv 2009;6:827-34.
114. Lungwitz U, Breunig M, Blunk T, Gopferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 2005;60:247-66.
115. Choi SW, Lee SH, Mok H, Park TG. Multifunctional siRNA delivery system: polyelectrolyte complex micelles of six-arm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide. Biotechnol Prog 2010;26:57-63.
116. Oliveira S, van Rooy I, Kranenburg O, Storm G, Schiffelers RM. Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. Int J Pharm 2007;331:211-4.
117. Hou KK, Pan H, Ratner L, Schlesinger PH, Wickline SA. Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides. ACS Nano 2013;7:8605-15.
118. Zuhorn IS, Engberts JB, Hoekstra D. Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J 2007;36:349-62.
119. Kim SI, Shin D, Choi TH, Lee JC, Cheon GJ, et al. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol Ther 2007;15:1145-52.
120. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008;26:561-9.
121. Lee SK, Siefert A, Beloor J, Fahmy TM, Kumar P. Cell-specific siRNA delivery by peptides and antibodies. Methods Enzymol 2012;502:91-122.
122. Cesarone G, Edupuganti OP, Chen CP, Wickstrom E. Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1. Bioconjug Chem 2007;18:1831-40.
123. Lorenz C, Hadwiger P, John M, Vornlocher HP, Unverzagt C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 2004;14:4975-7.
124. Blum JS, Saltzman WM. High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine. J Control Release 2008;129:66-72.
125. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001;47:113-31.
126. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 2006;5:1708-13.
128. Deng J, Guo Y, Jiang Z, Yang M, Li H, et al. Enhancement of ovarian cancer chemotherapy by delivery of multidrug-resistance gene small interfering RNA using tumor targeting Salmonella. J Obstet Gynaecol Res 2015;41:615-22.
129. Huang YH, Bao Y, Peng W, Goldberg M, Love K, et al. Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc Natl Acad Sci U S A 2009;106:3426-30.
130. Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, et al. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med 2012;4:147ra12.
131. Ma J, Kala S, Yung S, Chan TM, Cao Y, et al. Blocking stemness and metastatic properties of ovarian cancer cells by targeting p70(S6K) with dendrimer nanovector-based siRNA delivery. Mol Ther 2018;26:70-83.
132. van den Brand D, Mertens V, Massuger L, Brock R. siRNA in ovarian cancer - Delivery strategies and targets for therapy. J Control Release 2018;283:45-58.
133. Halbur C, Choudhury N, Chen M, Kim JH, Chung EJ. siRNA-conjugated nanoparticles to treat ovarian cancer. SLAS Technol 2019;24:137-50.
134. Meng X, Joosse SA, Muller V, Trillsch F, Milde-Langosch K, et al. Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients. Br J Cancer 2015;113:1358-66.
135. Zhou J, Gong G, Tan H, Dai F, Zhu X, et al. Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. Oncol Rep 2015;33:2915-23.
136. Guo F, Tian J, Lin Y, Jin Y, Wang L, et al. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma. J Int Med Res 2013;41:1456-61.
137. Yoshimura A, Sawada K, Nakamura K, Kinose Y, Nakatsuka E, et al. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells. BMC Cancer 2018;18:1065.
138. Xu Y, Xu L, Zheng J, Geng L, Zhao S. MiR-101 inhibits ovarian carcinogenesis by repressing the expression of brain-derived neurotrophic factor. FEBS Open Bio 2017;7:1258-66.
139. Zuberi M, Khan I, Mir R, Gandhi G, Ray PC, et al. Utility of Serum miR-125b as a diagnostic and prognostic indicator and its alliance with a panel of tumor suppressor genes in epithelial ovarian cancer. PLoS One 2016;11:e0153902.
140. Chao A, Lai CH, Chen HC, Lin CY, Tsai CL, et al. Serum microRNAs in clear cell carcinoma of the ovary. Taiwan J Obstet Gynecol 2014;53:536-41.
141. Wu H, Xiao Z, Wang K, Liu W, Hao Q. MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1. Biochem Biophys Res Commun 2013;441:693-700.
142. Zuberi M, Mir R, Khan I, Javid J, Guru SA, et al. The promising signatures of circulating microRNA-145 in epithelial ovarian cancer patients. Microrna 2019; doi: 10.2174/2211536608666190225111234.
143. Gong L, Wang C, Gao Y, Wang J. Decreased expression of microRNA-148a predicts poor prognosis in ovarian cancer and associates with tumor growth and metastasis. Biomed Pharmacother 2016;83:58-63.
144. Chen H, Zhang L, Zhang L, Du J, Wang H, et al. MicroRNA-183 correlates cancer prognosis, regulates cancer proliferation and bufalin sensitivity in epithelial ovarian caner. Am J Transl Res 2016;8:1748-55.
145. Ren X, Zhang H, Cong H, Wang X, Ni H, et al. Diagnostic model of serum miR-193a-5p, HE4 and CA125 improves the diagnostic efficacy of epithelium ovarian cancer. Pathol Oncol Res 2018;24:739-44.
146. Benson EA, Skaar TC, Liu Y, Nephew KP, Matei D. Carboplatin with decitabine therapy, in recurrent platinum resistant ovarian cancer, alters circulating miRNAs concentrations: a pilot study. PLoS One 2015;10:e0141279.
147. Zuberi M, Khan I, Gandhi G, Ray PC, Saxena A. The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer. Tumour Biol 2016;37:11259-66.
148. Márton E, Lukacs J, Penyige A, Janka E, Hegedus L, et al. Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer. J Biotechnol 2019;297:58-65.
149. Meng X, Muller V, Milde-Langosch K, Trillsch F, Pantel K, et al. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget 2016;7:16923-35.
150. Zuberi M, Mir R, Das J, Ahmad I, Javid J, et al. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features. Clin Transl Oncol 2015;17:779-87.
151. Su YY, Sun L, Guo ZR, Li JC, Bai TT, et al. Upregulated expression of serum exosomal miR-375 and miR-1307 enhance the diagnostic power of CA125 for ovarian cancer. J Ovarian Res 2019;12:6.
152. Yang L, Wei QM, Zhang XW, Sheng Q, Yan XT. MiR-376a promotion of proliferation and metastases in ovarian cancer: Potential role as a biomarker. Life Sci 2017;173:62-7.
153. Tang X, Zeng X, Huang Y, Chen S, Lin F, et al. miR-423-5p serves as a diagnostic indicator and inhibits the proliferation and invasion of ovarian cancer. Exp Ther Med 2018;15:4723-30.
154. Salem M, O’Brien JA, Bernaudo S, Shawer H, Ye G, et al. miR-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2-versican pathway. Cancer Res 2018;78:4175-90.
155. Chen X, Ying X, Wang X, Wu X, Zhu Q, et al. Exosomes derived from hypoxic epithelial ovarian cancer deliver microRNA-940 to induce macrophage M2 polarization. Oncol Rep 2017;38:522-8.
156. Günel T, Gumusoglu E, Dogan B, Ertem FB, Hosseini MK, et al. Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer. Arch Gynecol Obstet 2018;298:1173-80.
157. Qiu JJ, Lin XJ, Tang XY, Zheng TT, Lin YY, et al. Exosomal metastasisassociated lung adenocarcinoma transcript 1 promotes angiogenesis and predicts poor prognosis in epithelial ovarian cancer. Int J Biol Sci 2018;14:1960-73.
158. Ma J, Xue M. LINK-A lncRNA promotes migration and invasion of ovarian carcinoma cells by activating TGF-beta pathway. Biosci Rep 2018;38.
159. Zhang H, Yao B, Tang S, Chen Y. LINK-A long non-coding RNA (lncRNA) participates in metastasis of ovarian carcinoma and upregulates hypoxia-inducible factor 1 (HIF1alpha). Med Sci Monit 2019;25:2221-7.
161. Wang X, Han L, Zhou L, Wang L, Zhang LM. Prediction of candidate RNA signatures for recurrent ovarian cancer prognosis by the construction of an integrated competing endogenous RNA network. Oncol Rep 2018;40:2659-73.
162. Wang Y, Zhang X, Tang W, Lin Z, Xu L, et al. miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-kappaB in high-grade serous ovarian carcinoma. Cell Death Differ 2017;24:2089-100.
163. Li N, Yang L, Wang H, Yi T, Jia X, et al. MiR-130a and MiR-374a function as novel regulators of cisplatin resistance in human ovarian cancer A2780 cells. PLoS One 2015;10:e0128886.
164. Zhang Y, Chen Q. Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer. Braz J Med Biol Res 2017;50:e6104.
165. Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, et al. Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia 2009;11:529-41.
166. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 2012;31:4567-76.
167. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008;8:187-98.
168. Gasparri ML, Besharat ZM, Farooqi AA, Khalid S, Taghavi K, et al. MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance. J Cancer Res Clin Oncol 2018;144:2313-8.
169. Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, et al. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 2012;40:761-74.
170. Du W, Feng Z, Sun Q. LncRNA LINC00319 accelerates ovarian cancer progression through miR-423-5p/NACC1 pathway. Biochem Biophys Res Commun 2018;507:198-202.
171. Meng L, Liu B, Ji R, Jiang X, Yan X, et al. Targeting the BDNF/TrkB pathway for the treatment of tumors. Oncol Lett 2019;17:2031-9.
172. Zheng HB, Zheng XG, Liu BP. miRNA-101 inhibits ovarian cancer cells proliferation and invasion by down-regulating expression of SOCS-2. Int J Clin Exp Med 2015;8:20263-70.
173. Guo F, Cogdell D, Hu L, Yang D, Sood AK, et al. MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol Rep 2014;31:2021-8.
174. Zavesky L, Jandakova E, Weinberger V, Minar L, Hanzikova V, et al. Ascites-derived extracellular microRNAs as potential biomarkers for ovarian cancer. Reprod Sci 2019;26:510-22.
175. Press JZ, Reyes M, Pitteri SJ, Pennil C, Garcia R, et al. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration. Int J Gynecol Cancer 2012;22:546-52.
176. Braga EA, Fridman MV, Kushlinskii NE. Molecular mechanisms of ovarian carcinoma metastasis: key genes and regulatory MicroRNAs. Biochemistry (Mosc) 2017;82:529-41.
177. Zhou J, Zhang C, Zhou B, Jiang D. miR-183 modulated cell proliferation and apoptosis in ovarian cancer through the TGF-beta/Smad4 signaling pathway. Int J Mol Med 2019;43:1734-46.
178. Yan H, Li H, Li P, Li X, Lin J, et al. Long noncoding RNA MLK7-AS1 promotes ovarian cancer cells progression by modulating miR-375/YAP1 axis. J Exp Clin Cancer Res 2018;37:237.
179. Zou J, Liu L, Wang Q, Yin F, Yang Z, et al. Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1. Am J Transl Res 2017;9:1357-68.
180. Meng X, Muller V, Milde-Langosch K, Trillsch F, Pantel K, et al. Circulating cell-free miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Adv Exp Med Biol 2016;924:3-8.
181. Koutsaki M, Libra M, Spandidos DA, Zaravinos A. The miR-200 family in ovarian cancer. Oncotarget 2017;8:66629-40.
182. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007;67:7972-6.
183. Kong F, Sun C, Wang Z, Han L, Weng D, et al. miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technolog Med Sci 2011;31:543.
184. Dong R, Liu X, Zhang Q, Jiang Z, Li Y, et al. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget 2014;5:10816-29.
185. Zhu X, Li Y, Xie C, Yin X, Liu Y, et al. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer 2014;135:1286-96.
186. Hu J, Wang L, Chen J, Gao H, Zhao W, et al. The circular RNA circ-ITCH suppresses ovarian carcinoma progression through targeting miR-145/RASA1 signaling. Biochem Biophys Res Commun 2018;505:222-8.
187. Song K, Lv T, Chen Y, Diao Y, Yao Q, et al. Emodin inhibits TGF-beta2 by activating the FOXD3/miR199a axis in ovarian cancer cells in vitro. Oncol Rep 2018;39:2063-70.
188. Bryzgunova OE, Laktionov PP. Extracellular nucleic acids in urine: sources, structure, diagnostic potential. Acta Naturae 2015;7:48-54.
189. Sun Y, Ma L. New insights into long non-coding RNA MALAT1 in cancer and metastasis. Cancers (Basel) 2019;11.
190. Smith B, Agarwal P, Bhowmick NA. MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine. Endocr Relat Cancer 2017;24:R157-R72.
191. Zhang L, Liao Y, Tang L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res 2019;38:53.
192. Adams BD, Parsons C, Slack FJ. The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas. Expert Opin Ther Targets 2016;20:737-53.
193. Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs 2017;35:180-8.
194. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-5.
195. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
196. Schwarzenbach H, Machado da Silva A, Calin G, Pantel K. Data Normalization Strategies for MicroRNA Quantification. Clin Chem 2015; doi: 10.1373/clinchem.2015.239459.
197. Bronkhorst AJ, Aucamp J, Pretorius PJ. Cell-free DNA: preanalytical variables. Clin Chim Acta 2015;450:243-53.
